Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

3.9K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.9K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K
Immunological Memory01:23

Immunological Memory

14.7K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.7K
Active versus Passive Immunity01:31

Active versus Passive Immunity

9.7K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
9.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

399
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.2K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same author

Diminishing Returns of Novel Autoantibody Discovery in Encephalitis.

JAMA neurology·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Autologous haematopoietic stem cell transplantation in multiple sclerosis: outcomes and predictors from German real-world data.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.

Neurological research and practice·2026
Same author

Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: Dec 26, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.3K

Transient MOG antibody seroconversion associated with immunomodulating therapy.

Marc Pawlitzki1, Christin Campe2, Leoni Rolfes3

  • 1Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.

Multiple Sclerosis and Related Disorders
|March 17, 2020
PubMed
Summary
This summary is machine-generated.

A patient seronegative for myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) became MOG-IgG positive during interferon-beta treatment. This suggests interferon-beta may influence MOG-IgG seroconversion in autoimmune CNS demyelination.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K

Related Experiment Videos

Last Updated: Dec 26, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.3K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K

Area of Science:

  • Neuroimmunology
  • Autoimmune Neurology
  • Demyelinating Diseases

Background:

  • Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) autoantibodies are linked to central nervous system (CNS) demyelination.
  • Accurate MOG-IgG detection is crucial for diagnosing and managing these autoimmune conditions.

Observation:

  • A 35-year-old patient presented with two corticosteroid-responsive episodes of brainstem encephalitis and optic neuritis.
  • The patient was initially seronegative for MOG-IgG across three independent immunoassays.
  • MOG-IgG seroconversion was observed after initiating interferon-beta (IFN-beta) therapy six months post-initial attack.

Findings:

  • Interferon-beta (IFN-beta) treatment coincided with the development of MOG-IgG positivity.
  • MOG-IgG serum levels decreased upon switching therapy to glatiramer acetate.
  • This case supports previous findings on IFN-beta's potential role in exacerbating antibody-mediated disorders.

Implications:

  • Interferon-beta may induce seroconversion in MOG-IgG-negative patients with suspected autoimmune demyelination.
  • Careful monitoring for MOG-IgG seroconversion is warranted in patients treated with IFN-beta.
  • This highlights the complex interplay between therapeutic interventions and autoantibody status in CNS demyelinating diseases.